Page last updated: 2024-08-07 16:38:48
Glutamate receptor 2
A glutamate receptor 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P42262]
Synonyms
GluR-2;
AMPA-selective glutamate receptor 2;
GluR-B;
GluR-K2;
Glutamate receptor ionotropic, AMPA 2;
GluA2
Research
Bioassay Publications (29)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 13 (44.83) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
Compounds (59)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| aminolevulinic acid | Homo sapiens (human) | Ki | 790.0000 | 1 | 1 |
| 5-aminovaleric acid | Homo sapiens (human) | Ki | 17,400.0000 | 1 | 1 |
| alanylalanine | Homo sapiens (human) | Ki | 120.0000 | 1 | 1 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | IC50 | 0.1353 | 3 | 3 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | Ki | 0.0170 | 1 | 1 |
| gyki 52466 | Homo sapiens (human) | Ki | 4.5000 | 2 | 2 |
| kainic acid | Homo sapiens (human) | Ki | 12.2070 | 3 | 3 |
| glycylglycine | Homo sapiens (human) | Ki | 1,000.0000 | 1 | 1 |
| glutamic acid | Homo sapiens (human) | IC50 | 0.6130 | 1 | 1 |
| glutamic acid | Homo sapiens (human) | Ki | 0.9400 | 3 | 3 |
| selfotel | Homo sapiens (human) | IC50 | 0.9670 | 1 | 1 |
| leucyl-alanine | Homo sapiens (human) | Ki | 120.0000 | 1 | 1 |
| alanylproline | Homo sapiens (human) | Ki | 150.0000 | 1 | 1 |
| glycylleucine | Homo sapiens (human) | Ki | 160.0000 | 1 | 1 |
| alanyltyrosine | Homo sapiens (human) | Ki | 150.0000 | 1 | 1 |
| glycylsarcosine | Homo sapiens (human) | Ki | 830.0000 | 1 | 1 |
| glycylaspartic acid | Homo sapiens (human) | Ki | 350.0000 | 1 | 1 |
| histidinoalanine | Homo sapiens (human) | Ki | 480.0000 | 1 | 1 |
| argiotoxin-636 | Homo sapiens (human) | IC50 | 152.7500 | 2 | 2 |
| 2-amino-3-(3-(carboxymethoxy)-5-methylisoxazol-4-yl)propionic acid | Homo sapiens (human) | IC50 | 93.0000 | 2 | 2 |
| 5-fluorowillardiine | Homo sapiens (human) | Ki | 0.0251 | 1 | 1 |
| ly 293558 | Homo sapiens (human) | IC50 | 3.0750 | 2 | 2 |
| ly 293558 | Homo sapiens (human) | Ki | 2.9025 | 4 | 4 |
| alanylglutamic acid | Homo sapiens (human) | Ki | 320.0000 | 1 | 1 |
| prolyl-tyrosine | Homo sapiens (human) | Ki | 730.0000 | 1 | 1 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | Ki | 0.0619 | 2 | 2 |
| 5-bromowillardiine | Homo sapiens (human) | Ki | 0.1010 | 1 | 1 |
| prolylglutamic acid | Homo sapiens (human) | Ki | 20,000.0000 | 1 | 1 |
| cysteinylglycine | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| willardiine | Homo sapiens (human) | Ki | 0.8980 | 1 | 1 |
| aspartyl-aspartic acid | Homo sapiens (human) | Ki | 410.0000 | 1 | 1 |
| ly382884 | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| 4-bromohomoibotenic acid, (rs)-isomer | Homo sapiens (human) | Ki | 0.2500 | 1 | 1 |
| glycylproline | Homo sapiens (human) | Ki | 300.0000 | 1 | 1 |
| 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline | Homo sapiens (human) | IC50 | 2.5000 | 2 | 2 |
| 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline | Homo sapiens (human) | Ki | 0.2350 | 2 | 2 |
| 6-cyano-7-nitroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 1.0200 | 3 | 3 |
| fg 9041 | Homo sapiens (human) | IC50 | 1.5100 | 3 | 3 |
| fg 9041 | Homo sapiens (human) | Ki | 0.3600 | 1 | 1 |
| seryl-proline | Homo sapiens (human) | Ki | 130.0000 | 1 | 1 |
| lofepramine hydrochloride | Homo sapiens (human) | Ki | 13.0947 | 3 | 3 |
| phenylalanylalanine | Homo sapiens (human) | Ki | 110.0000 | 1 | 1 |
| acetylalanylalanine | Homo sapiens (human) | Ki | 30,000.0000 | 1 | 1 |
| alpha-aspartylalanine | Homo sapiens (human) | Ki | 320.0000 | 1 | 1 |
| alanyltyrosine | Homo sapiens (human) | Ki | 90.0000 | 1 | 1 |
| ubp 310 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| ubp 302 | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
| prolylglycine | Homo sapiens (human) | Ki | 22,000.0000 | 1 | 1 |
| glutamylalanine | Homo sapiens (human) | Ki | 250.0000 | 1 | 1 |
| phenylalanylphenylalanine | Homo sapiens (human) | Ki | 110.0000 | 1 | 1 |
| phenylalanyl-valine | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| alanylglycine | Homo sapiens (human) | Ki | 140.0000 | 1 | 1 |
| valyltyrosine | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| phenylalanylproline | Homo sapiens (human) | Ki | 130.0000 | 1 | 1 |
| glycylhistidine | Homo sapiens (human) | Ki | 1,000.0000 | 1 | 1 |
| prolyl-serine | Homo sapiens (human) | Ki | 14,000.0000 | 1 | 1 |
| prolylvaline | Homo sapiens (human) | Ki | 60.0000 | 1 | 1 |
| tqx 173 | Homo sapiens (human) | IC50 | 6.9500 | 2 | 2 |
| tqx 173 | Homo sapiens (human) | Ki | 16.8200 | 2 | 2 |
| 6-azido-7-nitro-1,4-dihydroquinoxaline-2,3-dione | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | Homo sapiens (human) | EC50 | 3.3100 | 1 | 1 |
| cyclothiazide | Homo sapiens (human) | EC50 | 38.4880 | 5 | 5 |
| kainic acid | Homo sapiens (human) | EC50 | 34.0350 | 2 | 2 |
| glutamic acid | Homo sapiens (human) | EC50 | 722,116,393.1444 | 8 | 11 |
| 5-fluorowillardiine | Homo sapiens (human) | EC50 | 0.4630 | 1 | 1 |
| gyki 53655 | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| 4-bromohomoibotenic acid, (rs)-isomer | Homo sapiens (human) | EC50 | 39.4800 | 5 | 5 |
| ly 404187 | Homo sapiens (human) | EC50 | 1.0135 | 4 | 4 |
| 4-ethyl-7-fluoro-3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxide | Homo sapiens (human) | Kd | 5.6000 | 1 | 1 |
| 4-cyclopropyl-7-fluoro-3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxide | Homo sapiens (human) | EC50 | 0.8114 | 1 | 2 |
| 4-cyclopropyl-7-fluoro-3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxide | Homo sapiens (human) | Kd | 0.3500 | 1 | 1 |
Drugs with Other Measurements
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS)-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO).Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships.Journal of medicinal chemistry, , Aug-29, Volume: 40, Issue:18, 1997
Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.Journal of medicinal chemistry, , Volume: 34, Issue:1, 1991
Studies on Aryl-Substituted Phenylalanines: Synthesis, Activity, and Different Binding Modes at AMPA Receptors.Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists.Journal of medicinal chemistry, , May-18, Volume: 43, Issue:10, 2000
4-Alkylidenyl glutamic acids, potent and selective GluR5 agonists.Bioorganic & medicinal chemistry letters, , Aug-21, Volume: 10, Issue:16, 2000
Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues.Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Functional characterization of Tet-AMPA [tetrazolyl-2-amino-3-(3-hydroxy-5-methyl- 4-isoxazolyl)propionic acid] analogues at ionotropic glutamate receptors GluR1-GluR4. The molecular basis for the functional selectivity profile of 2-Bn-Tet-AMPA.Journal of medicinal chemistry, , Aug-23, Volume: 50, Issue:17, 2007
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.Journal of medicinal chemistry, , Nov-03, Volume: 48, Issue:22, 2005
4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists.Journal of medicinal chemistry, , May-18, Volume: 43, Issue:10, 2000
4-Alkylidenyl glutamic acids, potent and selective GluR5 agonists.Bioorganic & medicinal chemistry letters, , Aug-21, Volume: 10, Issue:16, 2000
Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacy.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 23, Issue:23, 2013
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.Journal of medicinal chemistry, , Aug-12, Volume: 53, Issue:15, 2010
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.Journal of medicinal chemistry, , Dec-08, Volume: 38, Issue:25, 1995
(3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.Journal of medicinal chemistry, , Jul-09, Volume: 36, Issue:14, 1993
Convergent synthesis and pharmacology of substituted tetrazolyl-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid analogues.Journal of medicinal chemistry, , May-05, Volume: 48, Issue:9, 2005
Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (RS)-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO).Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands.Bioorganic & medicinal chemistry, , Feb-15, Volume: 18, Issue:4, 2010
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.Journal of medicinal chemistry, , Apr-05, Volume: 50, Issue:7, 2007
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.Journal of medicinal chemistry, , Apr-20, Volume: 49, Issue:8, 2006
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.European journal of medicinal chemistry, , Feb-05, Volume: 229, 2022
(3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.Journal of medicinal chemistry, , Dec-08, Volume: 38, Issue:25, 1995
Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.Journal of medicinal chemistry, , Oct-28, Volume: 53, Issue:20, 2010
A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 16, Issue:19, 2006
Positive allosteric modulators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors belonging to 4-cyclopropyl-3,4-dihydro-2h-1,2,4-pyridothiadiazine dioxides and diversely chloro-substituted 4-cyclopropyl-3,4-dihydro-2H-1,2,4-benzothiadJournal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
Positive allosteric modulators of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors belonging to 4-cyclopropyl-3,4-dihydro-2h-1,2,4-pyridothiadiazine dioxides and diversely chloro-substituted 4-cyclopropyl-3,4-dihydro-2H-1,2,4-benzothiadJournal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Enables
This protein enables 6 target(s):
| Target | Category | Definition |
|---|
| amyloid-beta binding | molecular function | Binding to an amyloid-beta peptide/protein. [GOC:hjd] |
| glutamate-gated receptor activity | molecular function | Catalysis of the transmembrane transfer of an ion by a channel that opens when glutamate has been bound by the channel complex or one of its constituent parts. [ISBN:0198506732] |
| AMPA glutamate receptor activity | molecular function | An ionotropic glutamate receptor activity that exhibits fast gating by glutamate and acts by opening a cation channel permeable to sodium, potassium, and, in the absence of a GluR2 subunit, calcium. [GOC:mah, PMID:10049997, PMID:8804111] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| ligand-gated monoatomic cation channel activity | molecular function | Enables the transmembrane transfer of an inorganic cation by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts. [GOC:mtg_transport, ISBN:0815340729] |
| transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | molecular function | Any transmitter-gated ion channel activity that is involved in regulation of postsynaptic membrane potential. [GO_REF:0000061, GOC:TermGenie, PMID:20200227] |
Located In
This protein is located in 11 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| external side of plasma membrane | cellular component | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. [GOC:dos, GOC:tb] |
| postsynaptic density | cellular component | An electron dense network of proteins within and adjacent to the postsynaptic membrane of an asymmetric, neuron-neuron synapse. Its major components include neurotransmitter receptors and the proteins that spatially and functionally organize them such as anchoring and scaffolding molecules, signaling enzymes and cytoskeletal components. [GOC:BHF, GOC:dos, GOC:ef, GOC:jid, GOC:pr, GOC:sjp, http://molneuro.kaist.ac.kr/psd, PMID:14532281, Wikipedia:Postsynaptic_density] |
| dendrite | cellular component | A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732] |
| endocytic vesicle membrane | cellular component | The lipid bilayer surrounding an endocytic vesicle. [GOC:mah] |
| asymmetric synapse | cellular component | A type of synapse occurring between an axon and a dendritic spine or dendritic shaft. Asymmetric synapses, the most abundant synapse type in the central nervous system, involve axons that contain predominantly spherical vesicles and contain a thickened postsynaptic density. Most or all synapses of this type are excitatory. [GOC:dgh, GOC:ef] |
| neuronal cell body | cellular component | The portion of a neuron that includes the nucleus, but excludes cell projections such as axons and dendrites. [GOC:go_curators] |
| dendritic spine | cellular component | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln] |
| excitatory synapse | cellular component | A synapse in which an action potential in the presynaptic cell increases the probability of an action potential occurring in the postsynaptic cell. [GOC:dph, GOC:ef] |
| postsynapse | cellular component | The part of a synapse that is part of the post-synaptic cell. [GOC:dos] |
| postsynaptic endocytic zone | cellular component | A stably positioned site of clathrin adjacent and physically attached to the postsynaptic specialization, which is the site of endocytosis of post-synaptic proteins. [PMID:17880892] |
Active In
This protein is active in 3 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| dendritic spine | cellular component | A small, membranous protrusion from a dendrite that forms a postsynaptic compartment, typically receiving input from a single presynapse. They function as partially isolated biochemical and an electrical compartments. Spine morphology is variable:they can be thin, stubby, mushroom, or branched, with a continuum of intermediate morphologies. They typically terminate in a bulb shape, linked to the dendritic shaft by a restriction. Spine remodeling is though to be involved in synaptic plasticity. [GOC:nln] |
| postsynaptic density membrane | cellular component | The membrane component of the postsynaptic density. This is the region of the postsynaptic membrane in which the population of neurotransmitter receptors involved in synaptic transmission are concentrated. [GOC:dos] |
Part Of
This protein is part of 1 target(s):
| Target | Category | Definition |
|---|
| AMPA glutamate receptor complex | cellular component | An assembly of four or five subunits which form a structure with an extracellular N-terminus and a large loop that together form the ligand binding domain. The C-terminus is intracellular. The ionotropic glutamate receptor complex itself acts as a ligand gated ion channel; on binding glutamate, charged ions pass through a channel in the center of the receptor complex. The AMPA receptors mediate fast synaptic transmission in the CNS and are composed of subunits GluR1-4, products from separate genes. These subunits have an extracellular N-terminus and an intracellular C-terminus. [GOC:ef] |
Involved In
This protein is involved in 7 target(s):
| Target | Category | Definition |
|---|
| signal transduction | biological process | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. [GOC:go_curators, GOC:mtg_signaling_feb11] |
| chemical synaptic transmission | biological process | The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:jl, MeSH:D009435] |
| ionotropic glutamate receptor signaling pathway | biological process | The series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, followed by the movement of ions through a channel in the receptor complex, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:signaling, ISBN:0198506732] |
| synaptic transmission, glutamatergic | biological process | The vesicular release of glutamate from a presynapse, across a chemical synapse, the subsequent activation of glutamate receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:dos] |
| regulation of postsynaptic membrane potential | biological process | Any process that modulates the potential difference across a post-synaptic membrane. [GOC:dph, GOC:ef] |
| monoatomic cation transmembrane transport | biological process | The process in which a monoatomic cation is transported across a membrane. Monatomic cations (also called simple cations) are positively charged ions consisting of exactly one atom. [GOC:dos, GOC:vw] |
| modulation of chemical synaptic transmission | biological process | Any process that modulates the frequency or amplitude of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. Amplitude, in this case, refers to the change in postsynaptic membrane potential due to a single instance of synaptic transmission. [GOC:ai] |